Mechanisms of resistance to apoptosis in human AML blasts: The role of differentiation-induced perturbations of cell-cycle checkpoints

Leukemia

Volumn 14, Issue 4, 2000, Pages 620-628

  Ketley, N J ^a,b   Allen, P D ^a   Kelsey, S M ^a   Newland, A C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Greenwich District Hospital   (United Kingdom)

Author keywords

AML; Apoptosis; Cell cycle; Chemotherapy; Differentiation

Indexed keywords

CALCITRIOL; IDARUBICIN; RETINOIC ACID; VINBLASTINE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROTECTION; CELL STRAIN HL 60; CELL STRAIN U937; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0034076366     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401715     Document Type: Article

References (50)

1. Griffin JD, Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986; 68: 1185-1195.
2. McCulloch EA. Stem cells in normal and leukemic hemopoiesis. Blood 1983; 62: 1-13.
3. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983; 62: 709-721.
4. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44: 3643-3653.
5. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
6. Marie J-P. P-glycoprotein in adult hematologic malignancies. In: Fisher GA, Sikic BI (eds). Drug Resistance in Clinical Oncology and Hematology. WB Saunders: Philadelphia, 1995, pp 239-250.
7. Filipits M, Suchomel RW, Zochbauer S, Malayeri R, Pirker R. Clinical relevance of drug resistance genes in malignant diseases. Leukemia 1996; 10: S10-S17.
8. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997; 11: 253-257.
9. 1 by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Diff 1995; 6: 361-370.
10. Meikrantz W, Schlegel R. Apoptosis and the cell cycle. J Cell Biochem 1995; 58: 160-174.
11. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 825-834.
12. Butturini A, Santucci MA, Gale RP, Perocco P, Tura S. GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy. Leukemia Res 1990; 14: 743-749.
13. Yang GS, Minden MD, McCulloch EA. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 1993; 7: 1012-1019.
14. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750-1757.
15. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New Engl J Med 1995; 332: 1671-1677.
16. Del Bino G, Li X, Traganos F, Darzynkiewicz Z. Altered susceptibility of differentiating HL60 cells to apoptosis induced by antitumor drugs. Leukemia 1994; 8: 281-288.
17. 2 vitamin D3 and granulocyte-macrophage colony-stimulating factor. Blood 1997; 90: 4578-4587.
18. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795-808.
19. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-556.
20. Xu H, Tepper CG, Jones JB, Fernandez CE, Studzinski GP. 1,25-dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression ot the Bcl-2 gene. Exp Cell Res 1993; 209: 367-374.
21. Cotter TG, Fernandes RS, Verhaegen S, McCarthy JV. Cell death in the myeloid lineage. Immunol Rev 1994; 142: 95-112.
22. Solary E, Bertrand R, Kohn KW, Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL60 cells by DNA topoisomerase I and II inhibitors. Blood 1993; 81: 1359-1368.
23. Zwelling LA, Chan D, Hinds M, Mayes J, Silberman LE, Blick M. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells. Cancer Res 1988; 48: 6625-6633.
24. Gunji H, Hass R, Kufe D. Internucleosomal DNA fragmentation during phorbol ester-induced monocytic differentiation and G0/G1 arrest. J Clin Invest 1992; 89: 954-960.
25. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994; 9: 3389-3396.
26. Jiang H, Lin J, Su Z, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397-3406.
27. 5 in HL60 cells. Cancer Res 1996; 56: 264-267.
28. 5 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142-153.
29. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992; 79: 2378-2383.
30. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL60 cells. Proc Nat Acad Sci USA 1985; 82: 790-794.
31. Paquette RL, Koeffler HP. Differentiation therapy. Hematol/Oncol Clin N Am 1992; 6: 687-706.
32. Olsson IL, Breitman TR. Induction of differentiation of the human histiocytic lymphoma cell line U937 by retinoic acid and cyclic adenosine 3′:5′-monophosphate-inducing agents. Cancer Res 1982; 42: 3924-3927.
33. Munker R, Norman A, Koeffler HP. Vitamin D compounds: effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 1986; 78: 424-430.
34. Obeid LM, Hannun YA. Ceramide: a stress signal and mediator of growth suppression and apoptosis. J Cell Biochem 1995; 58: 191-198.
35. Strum JC, Small GW, Pauig SB, Daniel LW. 1-β-D-arabinofuronosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem 1994; 269: 15493-15497.
36. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82: 405-414.
37. Emoto Y, Kisaki H, Manome Y, Kharbanda S, Kufe D. Activation of protein kinase Cδ in human myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood 1996; 87: 1990-1996.
38. 2 vitamin D3. Leukemia Res 1991; 15: 409-418.
39. Hass R, Pfannkuche H, Kharbanda S, Gunji H, Meyer G, Hartmann A, Hidaka H, Resch K, Kufe D, Goppelt-Strube M. Protein kinase C activation and protooncogene expression in differentiation/retrodifferentiation of human U-937 leukemia cells. Cell Growth Diff 1991; 2: 541-548.
40. Szabo E, Preis LH, Brown PH, Birrer MJ. The role of jun and fos gene family members in 12-o-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. Cell Growth Diff 1991; 10: 475-482.
41. Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B, Pantazis P, Kufe D. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 1991; 51: 6636-6642.
42. Ehinger M, Bergh G, Olofsson T, Baldetorp B, Olsson I, Gullberg U. Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemk U-937 cells. Blood 1996; 87: 1064-1074.
43. Fenaux P, Degos L. Treatment of acute promyelocytic leukaemia. In: Lowenberg B (ed). Acute Myelogenous Leukemia and Myelodysplasia. Bailliere Tindall: London, 1996, pp 107-128.
44. Venditti A, Stasi R, Del Poeta G, Buccisano F, Aronica G, Bruno A, Pisani F, Caravita T, Masi M, Tribalto M, Simone MD, Avvisati G, Amadori S, Papa G. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia. Leukemia 1995; 9: 1121-1125.
45. Tallman MS, Miller HJ, Zanzig C. All-trans retinoic acid, low-dose cytosine arabinoside and granulocyte colony-stimulating factor in acute myelogenous leukemia: update of an Illinois Cancer Centre phase II pilot study. Exp Hematol 1996; 24: 1125 (Abstr.).
46. Estey E, Beran M, Pierce S. All-trans retinoic acid (ATRA) may improve results of chemotherapy in poor prognosis non-APL AML and MDS: a randomised study. Blood 1997; 90: 416a (Abstr.).
47. Bradbury DA, Aldington S, Zhu Y-M, Russell NH. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol 1996; 94: 671-675.
48. Tallman MS. Differentiating therapy in acute myeloid leukemia. Leukemia 1996; 10: 1262-1268.
49. Studzinski GP, Reddy KB, Hill HZ, Bhandal AK. Potentiation of 1-β-D-arabinofuranosylcytocine cytotoxicity to HL-60 cells by 1,25-dihydroxyvitamin D3 correlates with reduced rate of maturation of DNA replication intermediates. Cancer Res 1991; 51: 3451-3455.
50. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood 1997; 89: 243-255.